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Abstract
Background: Assessments of vaccine efficacy and safety capture only the minimum information needed for
regulatory approval, rather than the full public health value of vaccines. Vaccine efficacy provides a measure of
proportionate disease reduction, is usually limited to etiologically confirmed disease, and focuses on the direct
protection of the vaccinated individual. Herein, we propose a broader scope of methods, measures and outcomes
to evaluate the effectiveness and public health impact to be considered for evidence-informed policymaking in
both pre- and post-licensure stages.
Discussion: Pre-licensure: Regulatory concerns dictate an individually randomised clinical trial. However, some
circumstances (such as the West African Ebola epidemic) may require novel designs that could be considered
valid for licensure by regulatory agencies. In addition, protocol-defined analytic plans for these studies should
include clinical as well as etiologically confirmed endpoints (e.g. all cause hospitalisations, pneumonias, acute
gastroenteritis and others as appropriate to the vaccine target), and should include vaccine-preventable disease incidence
and ‘number needed to vaccinate’ as outcomes.
Post-licensure: There is a central role for phase IV cluster randomised clinical trials that allows for estimation of population-
level vaccine impact, including indirect, total and overall effects. Dynamic models should be prioritised over static models
as the constant force of infection assumed in static models will usually underestimate the effectiveness and
cost-effectiveness of the immunisation programme by underestimating indirect effects. The economic impact
of vaccinations should incorporate health and non-health benefits of vaccination in both the vaccinated and
unvaccinated populations, thus allowing for estimation of the net social value of vaccination.
Conclusions: The full benefits of vaccination reach beyond direct prevention of etiologically confirmed
disease and often extend across the life course of a vaccinated person, prevent outcomes in the wider
community, stabilise health systems, promote health equity, and benefit local and national economies. The
degree to which vaccinations provide broad public health benefits is stronger than for other preventive and
curative interventions.
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Background
Evidence of vaccine efficacy and safety in the directly
vaccinated individual are the primary factors evaluated
when determining licensure. Regulatory decisions conse-
quently focus on benefit–risk ratios, as measured only
by vaccine efficacy and safety. However, measures of
vaccine efficacy and safety data capture only the mini-
mum information needed for regulatory approval, and
do not capture the full public health value of vaccines.
Vaccine efficacy derived from pre-licensure phase III
trials only provides a measure of proportionate disease
reduction, is usually limited to etiologically confirmed
disease, and focuses on direct protection in the vacci-
nated individual. As individually randomised trials
(iRCT) do not allow a full assessment of indirect vaccine
protection, relying only on them will underestimate the
public health value of vaccines that have high indirect
effects. Thus, all aspects of the public health value of
vaccines should be evaluated and incorporated into pub-
lic health decision-making. The full public health impact
of vaccinations should consider health and non-health
benefits of vaccination in both vaccinated and unvaccin-
ated populations. Indeed, the value chain goes beyond
efficacy and effectiveness to include the broader public
health impact (Fig. 1). Although safety is equally import-
ant in policymaking, methods for monitoring the safety
profile of vaccines have been addressed in other recent
publications [1, 2] and will not be re-addressed in this
paper.
To expand regulatory and policy discussions, the
Fondation Merieux organised a conference in June
2015 entitled Beyond Efficacy: The Full Public Health
Impact of Vaccines in Addition to Efficacy Measures
in Trials. As a result, a series of recommendations
have been published [3]. During the Geneva Health
Forum 2016, we further developed these recommen-
dations into a methodologically rigorous theoretical
framework. Herein, we propose a broader scope of
methods, measures and outcomes to evaluate the
effectiveness and public health impact of vaccines to
be considered for evidence-informed policymaking at
both the pre- and post-licensure level.
Disease and health outcomes
Definitions of efficacy and effectiveness
‘Efficacy’ is usually defined as the performance of an
intervention under ideal and controlled circumstances,
whereas ‘effectiveness’ refers to its performance under
‘real-world’ conditions. For the purpose of this manu-
script, we will apply a more rigorous mathematical def-
inition of efficacy as the proportionate reduction of the
incidence of the target infection in vaccinated subjects
compared to controls [4], equalling one minus the haz-
ard or risk ratio. For vaccine efficacy, we require that
vaccinated and unvaccinated people have the same ex-
posure risk to the target etiology, a condition best
achieved through randomised vaccine allocation.
Vaccine effectiveness is defined as the reduction of the
incidence for those receiving the vaccine intervention in
relation to direct, indirect, total and overall effectiveness
[5] (Fig. 2). As Fig. 2 indicates, indirect effectiveness
measures the reduction in incidence of unvaccinated
people in a population targeted for vaccination with a
varying level of immunisation coverage compared to that
for unvaccinated people in a totally unvaccinated
population.
Fig. 1 Value chain of vaccines
Fig. 2 Types of vaccine effectiveness, as developed by Halloran et al.
[34]. Cluster 1 has a fraction of the population vaccinated, while cluster
2 has no person vaccinated. The u and v indices designate vaccinated
and unvaccinated people, respectively. Direct effectiveness compares
the attack rate (AR) (or some other rate measure, e.g. incidence) of
vaccinated to unvaccinated people within a cluster, as in cluster 1.
Indirect effectiveness compares the AR in unvaccinated people in the
partially vaccinated cluster 1 to the AR in an unvaccinated cluster 2.
Total effectiveness compares the AR of vaccinated people in cluster 1
to the AR in cluster 2. Finally, overall effectiveness compares the AR
among all people in cluster 1 (i.e. vaccinated and unvaccinated) to the
AR among all people in cluster 2
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Methods to measure indirect effects in pre-licensure trials
An iRCT is the traditional method to measure vaccine
efficacy, evaluating a vaccine against a placebo or active
comparator with pre-specified endpoints to measure the
treatment effect size [6]. Such a trial design provides
data on direct vaccine efficacy but does not provide in-
formation on indirect, total and overall effects.
In addition to the lack of information on non-direct
vaccine effects, licensing trials have other limitations.
For rare outcomes, such as death, iRCTs may fail to re-
cruit sufficient sample sizes. For long-term outcomes,
such as neurologic sequelae of meningitis, licensing trials
may have insufficiently long follow-up periods. Etiologies
driven by largely unpredictable outbreaks, such as chol-
era, dengue, serogroup A meningococcus, Ebola and
others, may assume an importance well beyond their
disease burden since they can cause health system dis-
ruption, political instability and acute economic loss. Li-
censing trials based on an iRCT design may be difficult
to implement during an outbreak setting, are not opti-
mal for demonstrating a vaccine’s ability to prevent out-
breaks rather than individual cases of disease, and do
not provide information on a vaccine’s ability to prevent
health system disruption resulting from an outbreak or
epidemic. All of these issues may contribute to decision-
makers failing to appreciate the full benefits of a vaccine,
and thus delay its introduction.
In some circumstances, licensing trials may need to
rely on cluster-randomised clinical trial (cRCT) designs.
The advantage of cRCTs is that they support estimation
of population-level vaccine effects, including indirect,
total and overall effects (Fig. 2). Specifically, in a cRCT,
the main outcome is total vaccine effect, which includes
both direct and indirect effects. Indirect effects can be
measured independently by comparing unvaccinated
persons in intervention clusters (usually due to non-
compliance) to unvaccinated persons in control clusters.
If intervention clusters include individual-level random-
isation, one could retain the benefits of an iRCT by hav-
ing a true measure of vaccine efficacy as defined
previously. However, in this circumstance, indirect bene-
fits are fixed at the level seen by the vaccine coverage
dictated by the randomisation scheme and may not re-
flect real-world experience. Moreover, having an iRCT
nested within a cRCT presents considerable logistic
challenges.
An example of a cRCT design during an outbreak set-
ting was the ring vaccination trial of the replication-
competent vesicular stomatitis virus-based vaccine Ebola
vaccine candidate in Guinea, West Africa, during the
Ebola outbreak [5, 7]. The unit of randomisation was
contacts of an Ebola case and their contacts (i.e. contacts
of contacts). This approach allowed for faster recruit-
ment at a time when Ebola incident cases were declining
and the geographic location of the next cluster of cases
was unpredictable. The cluster in a cRCT could be a
household, neighbourhood, village, district or a network
of contacts. Despite this flexibility, several factors must
be considered. Clusters should be selected to reduce the
chance of movement of people and vectors between
clusters. A cRCT design could require a larger sample
size, but this may be counter-balanced by a higher event
rate if the cluster is a highly targeted at-risk population.
Unless the intervention arm is individually randomised,
a cRCT will not provide an unbiased measure of direct
vaccine efficacy. Lastly, cRCTs may be more difficult to
implement and thus cost more, take longer or increase
the risk of implementation failure. However, for many
vaccines where a high indirect effect is anticipated, such
disadvantages are far outweighed by the added informa-
tion provided through cRCTs. We suggest that regula-
tory authorities should consider allowing cRCTs to
become an acceptable additional pathway for licensure
when iRCTs are impractical or where high indirect
effects are anticipated.
Post-licensure evaluation of vaccines
Countries that introduce vaccines post-licensure should
plan to continue surveillance of the targeted disease to
allow evaluation of vaccine impact. Vaccine efficacy from
pre-licensure studies is often erroneously used as a sur-
rogate for predicting reductions in disease burden, but
inaccurately predicts impact for the reasons previously
discussed. Higher than expected post-licensure reduc-
tions will occur where a vaccine has a high indirect
effect. An additional issue can arise when burden reduc-
tion estimates are based on a surrogate. For example, for
pneumococcal conjugate vaccine (PCV), vaccine efficacy
against non-bacteremic pneumonia was based on vac-
cine efficacy for invasive pneumococcal disease. If the
former is substantially less than the latter, then disease
burden estimates would have been underestimated.
Since PCV has large indirect effects through reduction
of carriage, vaccine serotype pneumococcal pneumonia
would eventually be eliminated even with a lower
vaccine efficacy.
Lower than expected post-licensure reductions in dis-
ease burden may indicate problems with vaccine deliv-
ery, low immunisation coverage (due to programmatic
problems or vaccine hesitancy), cold chain limitations or
reflect different vaccine schedules compared to those
used in pre-licensure trials. In theory, lower than ex-
pected reductions may occur if lower efficacy or effect-
iveness is present in some epidemiological settings, such
as the hypothesis that observed lower rotavirus vaccine
efficacy in some settings occurred due to differences in
gut flora. Practically, however, we are not aware of cir-
cumstances in which licensing trials using an iRCT
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design overestimated disease burden reductions. For the
rotavirus vaccine trials, settings in which vaccine efficacy
was lower had a higher vaccine-preventable disease inci-
dence (VPDI) due to much larger background incidence
rates. Regardless, documenting and publicising vaccine
impact under real-life settings can provide important
public and political support for routine immunisation
programs. Post-licensure surveillance, including surveil-
lance for adverse events following immunisations, is also
important to identify rare adverse events or unexpected
effects. Robust vaccine impact data can help to counter
anti-vaccine messaging.
Methods
Post-licensure vaccine effectiveness trials are
population-specific trials that focus on estimating the
public health impact of the vaccine in a particular
setting under real world conditions [4]. Most post-
licensure studies are observational given the ethical
issues of withholding a licensed vaccine from a con-
trol group. Under some circumstances, however, ran-
domised studies may be conducted. For example, if
disease burden is unknown (and thus a vaccine would
not be introduced), a vaccine can be used in a probe
study approach [8], as occurred during a Haemophilus
influenzae type b (Hib) vaccine trial in Indonesia [9].
Vaccine introduction may also need to be imple-
mented in stages due to programmatic, product or
financial limitations that would allow for a stepped
wedge design, although, for a variety of reasons, this
design has almost never been used in a vaccine trial
[10, 11].
A last justification for a randomised trial using a clus-
ter design in the post-licensure phase may be to demon-
strate vaccine performance (including vaccine efficacy
and impact) in a resource-poor setting where many
health priorities compete for scarce health sector fund-
ing. In this case, cluster randomisation is particularly im-
portant since the goal is to provide as accurate an
estimate as possible of vaccine-associated reductions in
adverse health outcomes. One example of this was a
phase IV double-blind, placebo-controlled trial of a two-
dose regimen of bivalent killed whole-cell oral cholera
vaccine over 5 years in a slum area of Kolkata, India
[12]. A second example is a phase IV trial for a single
dose of the Vi polysaccharide typhoid vaccine in slum-
dwelling residents of Kolkata, India [13].
Mathematical models can be used to extrapolate from
the results of clinical trials to estimate the impact of vac-
cination programmes. The models that are used for this
purpose can be classified as dynamic or static. Dynamic
transmission models (often shortened to ‘dynamic
models’) are able to capture the direct and indirect vac-
cine effects by assuming that the probability of a
susceptible individual becoming infected at any one
point in time (the force of infection) is related to the
number of infectious individuals in the population. If
this changes (for instance, vaccination would be ex-
pected to reduce the number of infectious individuals),
then the model recalculates the force of infection. Thus,
the remaining susceptible people experience a reduced
risk of infection through indirect protection [14, 15].
These assumptions closely mirror the real-world epi-
demiology of most vaccine-preventable diseases. Static
models, by contrast, do not recalculate the force of in-
fection – it remains at a fixed level (usually the pre-
vaccination level) – and therefore the remaining suscep-
tible individuals in the modelled population do not ex-
perience any indirect protection as a result of the
vaccination programme. By omitting indirect effects,
static models underestimate immunisation programme
impact. Despite this, static models remain widespread.
Indeed, most economic analyses of vaccination pro-
grammes employ these methods [16] and therefore
underestimate the cost-effectiveness of vaccination pro-
grammes. There are other, potentially important, effects
of vaccination programmes that are not captured by
static models, and that can be predicted by appropriately
parameterised dynamic models. These include increases
in the average age at infection following infant immun-
isation (which may have important public health conse-
quences if the risk of serious outcomes of infection
increases or decreases with age as is the case with ru-
bella and malaria, respectively) [15], increasing gaps be-
tween epidemics, and replacement of vaccine-targeted
serotypes with non-vaccine types (as has been demon-
strated with PCVs that target a relatively limited reper-
toire of the more than 90 pneumococcal serotypes).
These different effects, which are often vaccine-specific,
require the development of specific dynamic models.
Measures
We propose that the measures of VPDI, the number
needed to vaccinate (NNV) and total cases prevented
should be used in a more systematic manner for all vac-
cines [17, 18]. VPDI has several synonyms, including
vaccine-attributable risk and vaccine-attributable rate re-
duction. It is the incidence of a given disease syndrome
preventable by vaccine in a given context [19], and is de-
fined as “outcome incidence in an unvaccinated popula-
tion X vaccine efficacy” [8], and thus incorporates both
vaccine efficacy and the underlying burden of disease.
This is mathematically equivalent to the incidence in the
control group minus the incidence in the intervention
group. VPDI derived from a clinical trial is reported as
cases per 100,000 vaccinated persons per year for the
duration of the trial. In principle, and as indicated above,
VPDI is best calculated from cRCTs as this allows
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incorporation of the vaccine’s ability to prevent disease
through both direct and indirect mechanisms and, in
this case, it is the overall incidence reduction in the vac-
cinated population that is achievable with vaccine. By
contrast, VPDI calculated from an iRCT gives only the
reduction in incidence achievable from direct immunisa-
tion of individuals. Community randomised trials, how-
ever, are rare. For example, studies of PCV [9] and
rotavirus [17, 18] vaccines used iRCT designs to assess
VPDI against clinical outcomes; these studies likely
underestimated VPDI since rotavirus vaccine and PCV
provide indirect protection. Studies of dengue [20] and
the RTS,S malaria [10] vaccines similarly used an iRCT
design, but the consequence of this is unknown since
vaccination against vector-borne diseases affecting the
entire population may provide minimal transmission re-
ductions when the vaccine target age range is highly
constricted. An additional issue is that iRCTs and cRCTs
both usually target a limited age range even if indirect
benefits may accrue to other persons. For example,
PCVs may provide most of their benefit via indirect pro-
tection of unvaccinated older persons.
The NNV is often used as a metric of the value of vac-
cination programmes, and can also be used for cost ef-
fectiveness studies. NNV is a measure to quantify the
number of people that need to be vaccinated, or the
number of vaccine doses that need to be used, to pre-
vent one occurrence of a target health outcome [21].
Unlike VPDI, NNV is not a rate but instead the overall
number of cases prevented for a given number of per-
sons vaccinated, and thus incorporates the length of the
trial or, outside of a trial, the duration of immunity.
Consequently, if VPDI is reported as cases per 100,000
vaccinated persons per year, NNV is calculated as
100,000 divided by VPDI divided by length of study/im-
mune duration.
While VPDI and NNV can be calculated for etiologic-
ally confirmed outcomes, as public health measures,
these metrics have more utility when calculated for clin-
ical outcomes as this adjusts for the inevitable failure to
confirm all prevented outcomes. Although less specific
outcomes lead to lower vaccine efficacy, the baseline in-
cidence for less specific outcomes is often much higher,
leading to higher and more accurate VPDI estimates. For
example, during PCV trials in The Gambia [9] and
South Africa [22], the vaccine prevented approximately
4- to 5-fold more clinical pneumonia than vaccine sero-
type invasive pneumococcal disease. A trial of Hib con-
jugate vaccine in Indonesia used a community
randomised design to assess VPDI for clinical pneumo-
nia and suspected meningitis, and found a VPDI for all
clinical meningitis 10-fold higher than that for con-
firmed Hib meningitis [23]. Similar effects are seen in
developed countries and emphasise the difficulty in
accurately confirming etiology for all or even most cases
in which an organism forms part of the causal chain. For
example, in Finland, rotavirus VPDI was over twice as
high for all-cause compared to confirmed rotavirus acute
gastroenteritis [24].
Another advantage of focusing VPDI and NNV on
clinical outcomes is that clinical outcomes are usually of
greater public health importance and allow for more ac-
curate comparisons between vaccines. For example, pub-
lic health officials have a greater interest in preventing
hospitalisation for pneumonia than in preventing pneu-
monia through a serotype invasive pneumococcal disease
vaccine. When valuing a new vaccine such as for RTS,S
malaria or dengue, it may be more sensible, from a pub-
lic health perspective, to compare VPDI or NNV against
severe fever (or severe fever hospitalisations) rather than
VPDI or NNV for PCV or Hib vaccine impact against
severe pneumonia or rotavirus vaccine against severe
gastroenteritis [7].
Nevertheless, VPDI and NNV have some limitations.
Because these metrics incorporate baseline disease inci-
dence, they depend on the local epidemiological context
and thus require an appreciation of local epidemiological
nuances when extrapolating from one setting to another.
However, this may also represent an advantage since it
emphasises that decision-making around vaccines should
reflect not just the degree to which the vaccine works
against the target etiology but also how much disease
can potentially be prevented.
Outcomes
Outcomes should be those that are feasible, ethical and
of public health importance. Mortality is of the highest
public health importance. However, too few cases may
occur to make this a feasible outcome in all but the lar-
gest trials. Additionally, there is a moral imperative to
provide a certain standard of healthcare to study partici-
pants, decreasing mortality in trials even further. For ex-
ample, the RTS,S malaria vaccine trial was unable to
assess impact against malaria-related deaths because so
few subjects died irrelevant of their vaccination status
[25]. Disease syndromes often have higher public health
relevance for etiologically confirmed disease and, there-
fore, studies of PCV assessed impact against severe
pneumonia rather than invasive pneumococcal disease
as a primary outcome. In some instances, an outcome
can approximate both an etiology and a syndrome, for
example, in measles, malaria and dengue. In this case,
the primary advantage of using non-specific outcomes
(such as fever, or fever and rash) would be to assess the
degree to which diagnostic testing missed cases, for ex-
ample, through failure to suspect disease, failure to col-
lect a diagnostic specimen, laboratory error or imperfect
test sensitivity.
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Usually, severe disease is the optimal health outcome
to measure impact, and for some etiologies this is codi-
fied. However, severe disease case definitions often do
not exist. For example, no clinical trial case definition of
severe pneumonia currently exists. Studies have used
hospitalisation as a proxy, even though this is a utilisa-
tion and not a severity measure.
Table 1 summarises the pre- and post-licensure
methods, measures and outcomes for health outcomes.
Beyond health outcomes
The full public health impact of vaccinations should in-
corporate both the health and non-health benefits of
vaccination in both the vaccinated and unvaccinated
populations, i.e. including spillover effects (or indirect
effects or ‘externalities’) regarding all outcomes that
matter to the population or to policymakers. The inclu-
sion of internal and external non-health benefits in pub-
lic health impact is important since they allow
movement from standard cost-effectiveness analyses
(with health effects and direct and indirect healthcare
expenditure) to the estimation of the net social value of
vaccination [26]. The net social value should ideally cap-
ture internal and external vaccination effects on out-
comes such as educational attainment, employment,
income and social functioning – if those effects matter
to populations or policymakers. While such effects
should ideally be included in the estimation of public
health impacts of all health interventions, these effects
are particularly important for vaccinations because dis-
ease prevention in childhood often affects entire life tra-
jectories. For instance, a child’s economic future will be
very different if she becomes blind as a consequence of a
measles infection; however, the economic and social ef-
fects of blindness due to measles infection will not be
fully captured in standard efficacy, effectiveness and
cost-effectiveness analyses.
Methods
The causal effects of vaccinations on non-health out-
comes, such as education and income, can sometimes be
established in an iRCT. For instance, by revisiting chil-
dren who participated in iRCTs years after completion
of the trial, the causal effect of the vaccination on long-
term cognitive development and income can be deter-
mined (if the control group did not receive the vaccin-
ation after completion of the trial). However, in many
cases, it will be difficult to re-visit the trial subjects many
years later or subjects assigned to the control trial group
will have received the vaccination. Therefore, we also
need to use quasi-experiments to establish the long-
term effects of vaccinations on non-health outcomes in
both those receiving and those not receiving a vaccin-
ation. Quasi-experiments utilise quasi-random assign-
ment to intervention and control groups that results
from policy, clinical practice or ‘nature’. In quasi-
experiments, the unconfoundedness assumption re-
quired in non-experimental studies for causal inference
is replaced with other, often substantially weaker, as-
sumptions. Examples for such assumptions include the
exclusion restriction of instrumental variable analysis,
the continuity assumption of regression discontinuity
analysis, and the parallel trends assumption of
difference-in-differences analysis [27]. Quasi-
experiments have the advantage over many RCTs that
they typically generate causal evidence with a high de-
gree of external validity since they rely on routinely col-
lected outcome data and use real-life vaccination
policies and practices as exposure, i.e. they avoid the
artificial contexts that are often created by the selec-
tion criteria and processes in RCTs. Quasi-
experiments can often be carried out at low cost,
using routinely collected and retrospective data. They
further allow long-term follow-up of important health
and non-health outcomes of vaccinations in general
populations [28], which is useful for extended cost-
Table 1 Public Health impact of vaccines related to health outcomes
Health-related evaluations of impact
of vaccines
Conventional evaluations Additional ‘broader’ evaluations
Methods Pre-licensure
Individually randomised controlled Phase III trials
Post-licensure
Total and indirect effectiveness studies
Static modelling (assuming constant force of infection)
Pre-licensure
Cluster randomised controlled trials
Dynamic models
Post-licensure
Cluster randomised trials
Probe studies
Pre/post evaluations
Observational controlled studies
Measures Efficacy and effectiveness Vaccine preventable disease incidence
Number needed to vaccinate
Outcomes Morbidity and mortality at individual level All-cause mortality
Under 5 mortality
Non-etiologically confirmed clinical syndromes
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effectiveness analysis and to estimate the full public
health impact and net social value of vaccinations.
While quasi-experiments are still relatively rare in
vaccination studies, they are being increasingly uti-
lised in this field [29–31].
Measures and outcomes
Depending on the etiology and the reasons for using a
vaccine, outcomes other than those related to health
should be documented. As vaccination confers benefits
that are often neglected by traditional economic evalua-
tions, thereby resulting in sizeable undervaluation of
vaccination programmes [32], we propose moving from
a narrow economic focus, such as care-related product-
ivity gains and healthcare cost savings, to a broader
range of economic outcomes (Table 2). These additional
outcomes could include the vaccine programme’s impact
on spending on outbreak control, tourism (in particular
for vaccines that prevent or mitigate outbreaks), eco-
nomic productivity, and community health externalities in
terms of improved health outcomes for unvaccinated
community members [33].
Conclusions
At a pre-licensure level, we have outlined the limitations
of relying on efficacy data derived from assessment of
etiologically confirmed outcomes and the limitations of
the requirement for iRCTs as the only pathway to licen-
sure. Conventional pre-licensure trials exacerbate uncer-
tainties by focusing on measurement of vaccine efficacy
under idealised conditions [4]. iRCTs will hence often
grossly underestimate total vaccine impact by omitting
the indirect effects of vaccines and secondary outcomes
beyond morbidity and mortality at the individual level.
We suggest that, where iRCTs are not feasible, regula-
tory authorities should consider allowing cRCTs to be-
come an acceptable additional pathway for licensure and
reduce the divide between pre- and post-licensure evalu-
ations. While we acknowledge that regulatory concerns
often dictate an iRCT as the preferred design for phase
IIb or III vaccine efficacy trials, certain circumstances,
such as the Ebola epidemic or vaccines with anticipated
high indirect effects, do require designs such as the
cRCT, which should be considered valid for licensure by
regulatory agencies. Furthermore, analytic plan reporting
for pre-licensure phase III pivotal trials should always
include incidence rate reductions (VPDI) and NNV.
Additionally, the analytic plans should also ideally in-
clude assessment of vaccine impact on clinical as well as
etiologically confirmed outcomes (e.g. all cause hospitali-
sations, pneumonias, acute gastroenteritis and others, as
appropriate to the vaccine target). Finally, dynamic
mathematical models can be used to extrapolate from
the results of pre-licensure clinical trials to estimate the
impact of vaccination programmes.
At the post-licensure level, we have entered an era of
vaccine evaluation where all aspects of the public health
value of vaccines beyond efficacy should be assessed [3].
This is particularly important for vaccines with moderate
efficacy such as the RTS,S/AS01 malaria vaccine, CYD-
TDV dengue vaccine against non-hospitalised dengue
cases, and rotavirus vaccine in epidemiological settings
with a high disease burden. Phase IV trials that focus on
public health outcomes should ideally use a cRCT design
that allows for estimation of population-level vaccine
impact, including indirect, total and overall effects.
These measures provide a more complete indication of
the public health value of vaccines than just direct pro-
tection of individuals and report total vaccine impact on
outcome incidence rates. As these studies are not re-
quired for licensing purposes, vaccine manufacturers
often do not fund them, unless they are required to do
so as a post-authorisation commitment or for label up-
dates (e.g. seeking a new indication). Hence, such studies
are often funded by public health agencies or external
organisations such as The Bill & Melinda Gates Founda-
tion or Gavi. Nevertheless, the industry has been known
to fund such studies, depending on the alignment of in-
terests and resources; for example, in studies where they
think their product is underutilised because its value has
Table 2 Public health impact of vaccines related to non-health outcomes
Non-health related evaluations
of impact of vaccines
Traditional evaluations Additional ‘broader’ evaluations
Methods Cost-effectiveness analysis, informed by clinical
trials and costing studies
Extended cost effectiveness analysis, informed by quasi-
experiments
Measures and outcomes Healthcare cost savings
Care-related productivity gains
Health gains
Outcome- and behaviour-related productivity gains
Community health externalities (e.g. improved health outcomes
in unvaccinated community members)
Improved economic outcomes at the household and societal levels
Reduction in tourism loss
Averted outbreaks
Reduced health system disruption and impact on other diseases
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been underestimated in pre-licensure studies, and in
these cases may try to perform studies that can be gen-
eralised to a broader group of settings. Public health
agencies may fund studies to determine if a vaccine is
under- or overvalued in their population; external agen-
cies such as Gavi usually support such studies in
resource-limited settings.
Modelling is also a valuable tool, but dynamic models
should be prioritised over static models as the constant
force of infection assumed in static models will usually
underestimate the effectiveness and cost-effectiveness of
the immunisation programme by underestimating the
indirect effects [15]. Post-licensure quasi-experiments
allow long-term follow-up of important non-health out-
comes of vaccinations in general populations in order to
estimate the full public health impact and net social
value of vaccinations.
Policymakers should base their decision-making on a
broader range of measures and outcomes to more fully
assess a vaccine’s public health impact at the individual
and societal levels. We suggest expanding the tradition-
ally narrow focus (on direct reduction in morbidity/mor-
tality, care-related productivity gains and healthcare cost
savings) to a larger range of measures and outcomes.
The full public health impact of vaccinations should in-
corporate both the health and non-health benefits in
vaccinated and unvaccinated populations, i.e. include
indirect benefits and spillover effects (or ‘externalities’)
regarding all outcomes. Although such externalities and
indirect effects are important for all types of health
interventions, the a priori case for broader effects is
stronger for vaccinations than for any other health
intervention [29].
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